Regorafenib-associated hand–foot skin reaction: practical advice on diagnosis, prevention, and management

BACKGROUND: Regorafenib is an orally available, small-molecule multikinase inhibitor with international marketing authorizations for use in colorectal cancer and gastrointestinal stromal tumors. In clinical trials, regorafenib showed a consistent and predictable adverse-event profile, with hand–foot...

Descripción completa

Detalles Bibliográficos
Autores principales: McLellan, B., Ciardiello, F., Lacouture, M. E., Segaert, S., Van Cutsem, E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2015
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4576906/
https://www.ncbi.nlm.nih.gov/pubmed/26034039
http://dx.doi.org/10.1093/annonc/mdv244

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4576906/
https://www.ncbi.nlm.nih.gov/pubmed/26034039
http://dx.doi.org/10.1093/annonc/mdv244

Ejemplares similares